Patisiran · ONPATTRO
RNA / oligonucleotide
Evidence outlook
Approved: Transthyretin Amyloidosis with Polyneuropathy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (2)
- hATTR amyloidosis with polyneuropathy
- Hereditary transthyretin-mediated amyloidosis (hATTR) in adults with stage 1 or 2 polyneuropathy
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01960348 NCT01960348 · Transthyretin Amyloidosis with Polyneuropathy In this randomized, double-blind, placebo-controlled phase 3 trial, 225 participants received patisiran (148) or placebo (77). The hard clinical primary endpoint, change in mNIS+7 at 18 months, favored patisiran and was statistically significant: -6.03 versus 27.96 points, a between-group difference of -33.99 (p<0.0000001). Registry: NCT01960348 | 3 | Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo) 2017-08 | Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Competitive landscape
Other Transthyretin (TTR) drugs
Acoramidis, Eplontersen, Vutrisiran, Inotersen, Cliramitug and 3 more. Compare all 9 Transthyretin (TTR) drugs
This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Transthyretin Amyloidosis with Polyneuropathy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Patisiran (ONPATTRO): this drug | Approved | RNA / oligonucleotide | Transthyretin (TTR) | Reliable signal | NCT01960348: Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602) | |
| Acoramidis (Attruby) | Approved(overall) | Small molecule | Transthyretin (TTR) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Eplontersen (Wainua) | Approved | RNA / oligonucleotide | Transthyretin (TTR) | Weak signal | No reviewed efficacy summary in this indication | |
| Vutrisiran (AMVUTTRA) | Approved | RNA / oligonucleotide | Transthyretin (TTR) | Partial signal | NCT03759379: Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43) | |
| Inotersen (Tegsedi) | US approval withdrawn | RNA / oligonucleotide | Transthyretin (TTR) | Reliable signal | No reviewed efficacy summary in this indication | |
| Cliramitug | Phase 3(overall) | Monoclonal antibody | Transthyretin (TTR) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Coramitug | Phase 3(overall) | Monoclonal antibody | Transthyretin (TTR) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Nexiguran Ziclumeran | Phase 3(overall) | Gene therapy / editing | Transthyretin (TTR) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Nucresiran | Phase 3 | RNA / oligonucleotide | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent